The prolonged oncogenesis process (except in cases of hereditary MTC) suggests that people undergoing these therapies should be considered to be monitored regularly [73]; however, monitoring for the occurrence of MTC in patients taking GLP-1RAs (glucagon-like peptide-1 receptor agonists) is not recommended by the Food and Drug Administration (FDA). Here, GLP1R is linked to medullary thyroid gland carcinoma.